Spotlight

CEO Damien McDevitt, PhD, Featured in Biocom’s Article, “A Look at the Year Ahead for Life Sciences.”

by
iStock 1416621458 scaled e1674074751412 1

Aspen Neuroscience’s CEO, Damien McDevitt, PhD, was featured in Biocom California’s article, “A Look at the Year Ahead for Life Sciences.” Damien states, “The lack of treatment options for patients with neurodegenerative diseases remains a significant unmet medical need, especially options that slow down or cure the underlying disease pathogenesis. The development of cell therapy … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Kim Raineri and Andrés Bratt-Leal, PhD, presented at Phacilitate Advanced Therapies Week

by
Andrés Bratt Leal, PhD

Aspen Neuroscience’s Co-Founder and Senior Vice President of Research and Development, Andrés Bratt-Leal, PhD, and Chief Technology Officer, Kim Raineri, presented at the Advanced Therapies Week session, “Cell and Gene Therapy for Neurological Indications” on Friday, January 20th.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Selected as a Finalist for the Phacilitate Biotech Innovation Award

by
Untitled design 6

Aspen Neuroscience was selected as a finalist for the Biotech Innovation Award at the Advanced Therapies Awards at Phacilitate Advanced Therapies Week.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bank

by
Aspen Neuroscience Logo Icon

SAN DIEGO Calif., December 21, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), has signed a $40 million credit facility with Silicon Valley Bank (SVB). Deal terms were not disclosed.“We are pleased to work with Silicon Valley Bank. … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience’s Thorsten Gorba, PhD, and Xiaokui Zhang, PhD, Presented at the iPSC-Derived Cell Therapies Summit

by
Xiaokui and Thorsten

Aspen Neuroscience’s Chief Scientific Officer Xioakui Zhang, PhD, served as a panel member at the annual iPSC-Derived Cell Therapies Summit in Boston during “Industry Leaders’ Fireside Chat: Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies & Determining Future Outlook & Developments,” on Tuesday, December 6th. She reflected on current learnings from therapeutics development to drive … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience will Present at the Annual iPSC-Derived Cell Therapies Summit

by
IPSC Summit Logo 2022

We are looking forward to presenting this week at the annual iPSC-Derived Cell Therapies Summit in Boston. Xiaokui Zhang, PhD, Aspen’s Chief Scientific officer will serve as a panel member on Tuesday, December 6th at 8:30 a.m. during “Industry Leaders’ Fireside Chat: Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies & Determining Future … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience’s David Tastad, PhD, Presented at the Annual Society for Neuroscience Meeting

by
sfn1

Aspen Neuroscience’s David Tastad, PhD, presented the poster “Dopamine Neuron Regulation,” at the annual Society for Neuroscience (SFN) meeting on Sunday, November 13th. The presentation explored functional characterization of GBA1 mutations in iPSC-derived midbrain dopaminergic neurons.  “There was a great turnout at David’s poster at SFN 2022, a session packed with invigorating and collaborative discussions, … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Dr. Xiaokui Zhang to Present Aspen Neuroscience, Inc. at 2022 Cell & Gene on the Mesa

by
Xiaokui Zhang, PhD

SAN DIEGO, Oct. 11, 2022 — This week Xiaokui Zhang, Ph.D., Chief Scientific Officer of Aspen Neuroscience, Inc. will present at the 2022 Cell & Gene Meeting on the Mesa Conference in Carlsbad, Calif. including presenting a live corporate update and participating in a panel session to highlight new developments in the induced pluripotent stem cell (iPSC) field. This … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

NeuriTest™ Presented Publicly for the First Time at the International Society for Stem Cell Research Annual Meeting

by
Aspen Roy IMG 5026 Final Square scaled

SAN DIEGO, June 22, 2022 — Aspen Neuroscience, Inc. Director of Bioinformatics, Roy Williams, Ph.D., presented NeuriTest™ for the first time publicly last week at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting in San Francisco, Calif. Dr. Williams’ podium presentation, “NeuriTest: A Bioinformatics-based Tool for Quality Control of iPSC-derived Dopamine Neuron Precursors for Transplantation,” featured the advanced … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners

by
Aspen Neuroscience Series B

Will Fund Clinical Trials of Company’s First iPSC-derived Autologous Dopamine Neuron Replacement for Parkinson’s Disease FOR IMMEDIATE RELEASE CONTACT:Angelyn Lowemedia@aspenneuro.com SAN DIEGO, Calif., May 9, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), today announced the close of … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved